NY-APTORUM-GROUP
Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces that it has initiated investigational new drug (IND)-enabling studies for ALS-4, a small drug molecule candidate indicated for the treatment of infections caused by Staphylococcus aureus (or “S. aureus”) including methicillin-resistant Staphylococcus aureus (MRSA, i.e., one of the commonly known “super-bugs”) based on a novel anti-virulence approach.
The ALS-4 candidate has been progressing well and the first series of GLP toxicology studies have been completed through an appointed North American based contract research organization (CRO). In particular, ALS-4 candidate did not show any mutagenicity in the in vitro Ames tests. ALS-4 development is on track and the company targets to submit the related IND in the first half year of 2020 and a hybrid Phase 1 clinical study is currently planned in North America with both healthy volunteers and patients to obtain preliminary efficacy readout.
S. aureus is a bacteria which is a leading cause of blood, lung, skin, bone and device-related infections, as well as toxin-related diseases1 . It is estimated that patients with S. aureus bacteremia have an average mortality rate of 30%2 and that it is responsible for causing more deaths than AIDS, tuberculosis and viral hepatitis combined3 . MRSA and vancomycin-intermediate and resistant S. aureus have also been classified by the World Health Organization (WHO) as high priority pathogens for research and development4 .
About ALS-4
ALS-4 is a small molecule drug candidate that is believed to inhibit dehydrosqualene desaturase of S. aureus (incl. MRSA) which is involved in the generation of staphyloxanthin, a commonly visible “golden pigment” covering the bacteria and is primarily responsible for the bacteria’s resistance to attack from reactive oxygen species (ROS) deployed by phagocytic cells and neutrophils5 . On this basis, ALS-4 is not bactericidal and through inhibiting the production of staphyloxanthin, S. aureus becomes highly susceptible to the host’s immune clearance. ALS-4 deploys a novel approach towards the treatment of bacterial infection which is significantly different from the bactericidal approach found in most current antibiotics that are experiencing increasing drug resistance issues.
About Aptorum Group Limited
Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum Group is pursuing therapeutic projects in neurology, infectious diseases, gastroenterology, oncology and other disease areas.
For more information about Aptorum Group, please visit www.aptorumgroup.com .
Disclaimer and Forward-Looking Statements
This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company’s anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group’s Form 20-F and other filings that Aptorum Group may make with the SEC in the future. As a result, the projections included in such forward-looking statements are subject to change. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
1 Clin Microbiol Rev. 2015 Jul;28(3):603-61. 2 Clin Microbiol Rev. 2012 Apr;25(2):362-86 3 Van Hal et al. Clin Microbiol Rev 2012 5 mBio 2017 8(5): e01224-17 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20190909005043/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Clarity AI Acquires ecolytiq, Further Expanding Its AI Sustainability Solutions to End Consumers9.7.2025 13:00:00 CEST | Press release
The acquisition expands on Clarity AI’s market leading climate engagement offering for global retail and commercial banking financial institutions Clarity AI, one of the world’s largest and most awarded technology and AI firms in sustainability, today announced the acquisition of ecolytiq, a leading provider of in-app climate engagement solutions for financial institutions and their millions of retail and commercial banking customers globally. This strategic move further reinforces Clarity AI’s position at the forefront of the rapidly expanding sustainability tech sector, strengthening its dominance in delivering impactful, data-driven solutions that empower individuals and organizations to make more sustainable choices. With this acquisition, Clarity AI expands its class-leading product portfolio, serving a broad spectrum of market participants—from institutional investors and global corporations to retail banks and individual consumers. The company’s modular, AI-powered platform is d
Valorem Reply Brings AI-powered Image Recognition to Art Basel’s Global Fairs9.7.2025 12:57:00 CEST | Press release
Valorem Reply, part of the Reply Group and focused on delivering innovative digital solutions with Microsoft technologies, partnered with Art Basel – a premier international art fair that hosts shows in Basel, Hong Kong, Miami Beach, Paris and Qatar – to enhance the visitor experience. In partnership with Microsoft, they developed Art Basel Lens, a feature within the Art Basel Companion app that uses image recognition to provide real-time information about artworks directly to visitors’ smartphones, making it easier to explore and engage with the art on display. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250709262853/en/ With Valorem Reply, Art Basel introduced a mobile image recognition feature that connects audiences to artworks using Microsoft Azure. By scanning an artwork, visitors receive structured content about the piece, the artist, and the gallery. The feature supports a more autonomous and fluid exploration of
Venture Global andSEFEAnnounceExpansion of LNG Partnership9.7.2025 12:19:00 CEST | Press release
Today, Venture Global, Inc. (NYSE: VG) and Securing Energy for Europe GmbH (SEFE) announced the finalization of an agreement under which SEFE’s subsidiary, SEFE Energy GmbH, will purchase an additional 0.75 million tonnes per annum (MTPA) of liquefied natural gas (LNG) from CP2 LNG, Venture Global’s third project, for 20 years. Today’s announcement amends the existing Sales and Purchase Agreement signed by the companies in 2023, increasing the total volume of LNG purchased by SEFE from CP2 LNG to 3.0 MTPA. Venture Global is expected to become Germany’s largest LNG supplier, with a combined 5 MTPA of 20-year offtake agreements signed with SEFE and EnBW. In addition to its existing long-term agreements, Venture Global to date has supplied Germany with almost 80 cargoes of LNG from its Calcasieu Pass and Plaquemines LNG facilities, enough to power 8 million German homes for one year. “Venture Global is thrilled to expand our strategic partnership with Germany and SEFE and play a leading r
The MasterFrame 600, Cooler Master's Modular Full Tower for High-End Builds, Now Available in Europe9.7.2025 10:02:00 CEST | Press release
Inspired by the FreeForm 2.0 philosophy, this revolutionary open-frame chassis is now available across Europe at an MSRP of €199 Cooler Master, a global leader in PC hardware and innovative thermal solutions, today announced the European sales kick-off of the MasterFrame 600, a high-end, modular open-frame full tower designed for power users, creators, and PC modders seeking total creative freedom and high-performance potential. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250709203901/en/ Cooler Master's MasterFrame 600 is built on our FreeForm 2.0 philosophy offering owners more customization options for personal builds. The MasterFrame 600 is available across Europe at a suggested retail price of €199, exclusively through select partners and resellers. Engineered on Cooler Master’s FreeForm 2.0 platform, the MasterFrame 600 redefines what’s possible in a premium PC chassis. This open-frame full tower delivers exceptiona
Kaneka Obtains Halal Certificate for KANEKA UBIQUINOL TM9.7.2025 03:30:00 CEST | Press release
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Kazuhiko Fujii) (TOKYO:4118) has obtained “Halal Certificate (Certification Number: 355-TSRI/24)” for its functional food ingredient, KANEKA UBIQUINOLTM (active form of coenzyme Q10) powder, under the assessment of Shariah Research Institute of Takushoku University, and issued by JAPAN MUSLIM ASSOCIATION, a religious corporation, on May 28. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708279133/en/ Halal certificate Halal certification is a system in which relevant organizations verify that products or services do not contain ingredients prohibited under Shariah (Islamic law) and certify their compliance with Shariah. We actively pursue the acquisition of various certifications to ensure the safety and security of our raw materials, and we are pleased to announce that we have obtained a Halal Certificate for KANEKA UBIQUINOLTM. Currently, the Muslim populati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom